AstraZeneca has signed an AI-led research agreement with China's CSPC Pharmaceutical Group worth up to $5.3 billion, which ...

AstraZeneca (AZ) and CSPC Pharmaceuticals Group have entered into a partnership worth up to $5.3bn to develop therapies for ...

This trial evaluated the safety, tolerability, pharmacodynamics, pharmacokinetics and clinical activity of AstraZeneca’s ...

AstraZeneca has signed a research agreement worth more than $5 billion with Chinese drugmaker CSPC Pharmaceutical Group, the ...

Friday’s deal with fits neatly within AstraZeneca’s business development strategy of upping investments in AI and in China.

British drugmaker AstraZeneca unveiled on Friday an AI-assisted research partnership with Chinese counterpart CSPC ...

CSPC will use its artificial-intelligence-driven, dual-engine efficient drug discovery platform to analyze the binding ...

AstraZeneca could spend up to $5.3 billion in a deal to develop oral medicines with CSPC Pharmaceutical. Elsewhere, Insmed ...

Astra has agreed a deal that could be worth almost £4billion with a Chinese company to use AI in the production of new ...

The collaboration will focus on identifying pre-clinical candidates for high-priority targets, including a small molecule ...

Cambridge: AstraZeneca has entered a strategic research collaboration with Shijiazhuang City-based CSPC Pharmaceuticals Group ...

The collaboration aims to advance the discovery and development of novel oral candidates.